ClinicalTrials.gg
RecruitingNCT06722183FUTUREUpdated Dec 24, 2025

Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

A Phase 2 interventional study of Futibatinib orally administered and Tislelizumab (i.v. 200mg) in Colorectal Cancer, sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. Recruiting at 10 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies testing tislelizumab in Colorectal Neoplasms — 15 open to participants now, 19 under way, 1 of them phase 3. tislelizumab · Colorectal Neoplasms.

Planned enrollment
12th of 27
33 · median 33
Started
2025
with 5 others
Phase 2
20 of 27
10 open now
Primary completion
2028-03
later than 16 of 18 live
Registered
22nd of 27
by date
Lead sponsor
2 of 27
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Among the 27 studies testing tislelizumab in Colorectal Neoplasms, this one is the 12th largest by planned enrollment, is one of 6 that started in 2025, is one of 20 in phase 2, reaches primary completion later than 16 of the 18 other live ones, and was the 22nd registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

15 of the 27 studies testing tislelizumab in Colorectal Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing tislelizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The FUTURE trial is a prospective, multicentre, exploratory, open-label phase II platform trial. Its goal is to evaluate the efficacy, feasibility and safety of futibatinib combined with immunotherapeutic, targeted or chemotherapeutic agents in colorectal and other solid tumors and to additionally identify biomarkers that correlate with clinical outcome.

Read the detailed description

For the FUTURE-001 cohort:

All enrolled patients will take mFOLFOX 85 mg/m2 oxalipla n, 200 mg/m2 calcium folinate, 400 mg/m2 5-fluorouracil as bolus dose and 2400 mg/m2 5-fluorouracil as 48 h-infusion as standard chemotherapy on day 1, 15 and 29 of a 6-week cycle. Additionally, tislelizumab (i.v., 200 mg) is applied on day 1 and day 22. Futibatinib will be taken orally, once daily, continously. All patients enrolled will receive the study treatment for up to 12 months or until disease progression, unacceptable toxicity or patient's request or investigator's decision, whatever occurs first.

The primary objective is to evaluate the efficacy (primary endpoint: Overall Response Rate ORR, complete response + partial response) of futibatinib plus tislelizumab and chemotherapy in 1st-linetreatment of patients with colorectal cancer. The secondary objective is to evaluate further efficacy (duration of response (DoR, Progression-free survival (PFS), overall survival (OS)) as well as to assess safety and impact on the patients quality of life. Additionally, a correlation analysis between selected molecular parameters and clinical data to identify molecular biomarkers predictive for clinical outcome will be performed.

33 patients will be enrolled in this trial.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • platform trial
  • colorectal cancer
  • futibatinib
  • phase II
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient* provides signed .
  2. Patient is ≥ 18 years at the time of given informed consent.
  3. Patient has a proven solid tumor:

    • Specific for FUTURE-001: Histological or cytological confirmation of colorectal adenocarcinoma that is unresectable and/or with known RAS-, BRAF and MSI- status.
  4. Specific for FUTURE-001: Patient must agree to participation in the accompanying translational research program.
  5. Specific for FUTURE-001: Patient did not receive previous therapy in palliative setting ( situation).
  6. Patient has Performance status ≤ 1.
  7. Patient has adequate blood count, liver-enzymes, and renal function:

    1. > 1,500 cells/μL without the use of hematopoietic growth factors
    2. count ≥ 100 x 109/L (>100,000 per mm3)
    3. ≥ 9 g/dL, transfusion allowed
    4. Serum total ≤ 1.5x institutional upper normal limit () (or \< 2 x ULN in case of liver involvement or Gilbert's disease)
    5. (SGOT)/ALT (SGPT) ≤ 2.5 x institutional ULN without existing liver metastases, or ≤ 5 x UNL in the presence of liver metastases; AP ≤ 5 x ULN
    6. Patients not receiving therapeutic anticoagulation must have an ≤ 1.5 ULN and aPTT ≤ 1.5 ULN. The use of full dose anticoagulants is allowed as long as the INR or PTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least three weeks at the time of inclusion
    7. Serum Creatinine ≤ 1.5 x ULN and a calculated rate ≥ 50 mL /min
  8. Patient has serum calcium and phosphate levels within normal range.
  9. Female patients of or male patients with female partners of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use methods that result in a failure rate of \<1% per year during the treatment period and in FUTURE-001 for at least 1 week after last dose of futibatinib, 6 months after the last dose of chemotherapy or 4 months after last dose of tislelizumab, whatever is later. Male patients should refrain from sperm donation/ cryopreservation throughout this period and male patients with a pregnant partner must agree to remain abstinent or to use a condom for the duration of the pregnancy. Female patients of child-bearing potential must have a negative pregnancy test within the last 7 days prior to the start of trial therapy.
  10. Patient is willing and able to comply with the protocol (including contraceptive measures) for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

    • There is no data that indicates a specific gender distribution. Therefore, patients are included regardless of their gender.

Exclusion criteria

Exclusion Criteria:

  1. Specific for FUTURE-001: Patient has curative colorectal cancer.
  2. Patient received previous FGFR-addressed therapy with an FGFR inhibitor.
  3. Patient has known presence of tumors other than the entity investigated in the respective cohort (FUTURE-001: colorectal cancer) or a secondary tumor other than squamous or basal cell carcinomas of the skin or in situ carcinomas of the cervix which have been effectively treated. The sponsor decides to include patients who have received curative treatment and have been disease-free for at least 5 years
  4. Patient has known untreated or symptomatic CNS or .
  5. Patient has history and/or current evidence of any of the following disorders:

    1. Non-tumor related alteration of the calcium-phosphorus homeostasis that is considered in the opinion of the investigator
    2. Ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, or myocardia and lung, considered clinically significant in the opinion of the investigator
  6. Patient receives simultaneous, ongoing systemic immunotherapy, chemotherapy, or hormone anti-cancer therapy or any other anti-cancer treatment not described in the trial protocol (excluding palliative radiotherapy only for symptom control).
  7. Patient has a stage B cirrhosis according to criteria (or worse) or cirrhosis (of any grade) with a history of hepatic encephalopathy or clinically significant ascites resulting from cirrhosis. Clinically significant ascites is defined as ascites resulting from cirrhosis requiring diuretics or paracentesis.
  8. Patient has known allergic / hypersensitive reactions to at least one of the treatment components.
  9. Patient shows a ≥ grade 2 neuropathy
  10. Patient takes St. Johns Wort within 6 weeks prior to initiation of study treatment
  11. Patient has evidence of or any ongoing ophthalmological disorders. including but not limited to, central serous retinopathy, macular/retinal degeneration, diabetic retinopathy, and previous retinal detachment
  12. Patient has other serious illnesses or medical ailments within the last 12 months prior to the start of the study.
  13. Patient has a known presence of an active, uncontrollable infection.
  14. Patient has active disseminated intravascular coagulation.
  15. Patient has any other serious concomitant or medical condition that, in the opinion of the investigator, presents a high risk of complications to the patient or reduces the likelihood of clinical effect.
  16. Patient participated in another interventional clinical study within 28 days prior to study enrollment or participation in a clinical study at the same time as this study, unless it is an observational/ non-interventional study or during the follow-up period of an interventional study.
  17. Patient received treatment with any of the following within the specified time frame prior to the first dose of study treatment:

    1. Major surgery within 4 weeks (surgical incision should be fully healed)
    2. Radiotherapy for extended field within 4 weeks or limited field radiotherapy within 2 weeks
    3. Any drug within 4 weeks
  18. Female patients, who are pregnant or breast feeding or planning to become pregnant within 6 months after the end of treatment. Female patients of must have a negative serum pregnancy test result within 7 days prior to initiation of study treatment
  19. Specific for FUTURE-001: Patient received prior treatment with PD-(L)1 or targeted treatment
  20. Specific for FUTURE-001: Patient has any active disease or has a history of autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis , hyperthyroidism; patients with vitiligo; asthma that has been completely remitted in childhood and does not require any intervention in adulthood can be included; patients with asthma requiring medical intervention with bronchodilators cannot be included)
  21. Specific for FUTURE-001: Patient has immune deficiency or receives systemic hormone therapy (> 10mg/day prednisone or other equivalents), or other form of therapy within 2 weeks prior treatment initiation
  22. Specific for FUTURE-001: Patient has history of uncontrolled infection with human deficiency virus () or chronic infection with or C virus (HBV, )
  23. Specific for FUTURE-001: Patient has received a solid organ transplantation
  24. Specific for FUTURE-001: Patient has history of interstitial lung disease
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    Futibatinib plus tislelizumab plus mFOLFOX

    Futibatinib 20 mg orally, once daily, continuously, plus tislelizumab (i.v., 200 mg) on day 1 and day 22 at each 6-week cycle and mFOLFOX (SOC chemotherapy)

    Drug: Futibatinib orally administered · Drug: Tislelizumab (i.v. 200mg)

Interventions

  • DrugFutibatinib orally administered

    Futibatinib will be administered 20mg orally, once daily, continously

  • DrugTislelizumabStudies of TislelizumabTislelizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Tislelizumab (i.v. 200mg) will be administered on day 1 and day 22 of a 6-week cycle

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) according to RECIST v1.1

    ORR, defined as rate of patient who achieved complete or partial response (CR+PR) according to RECIST v1.1 as best response

    Time frame: up to 27 months

Secondary outcomes

  1. Duration of Response (DoR)

    (DoR), defined as time from response initiation (when either CR or PR is first determined) to date of progression or death to any cause

    Time frame: up to 27 months

  2. Progression-free survival (PFS) according to RECIST v1.1

    defined as time from date of enrollment to date of progression acc. to RECIST v1.1 or death due to any cause

    Time frame: every 8 weeks until disease progression, up to 27 months

  3. Overall Survival (OS)

    time from date of enrollment date of death due to any cause

    Time frame: up to 27 months

  4. Safety

    assessment of safety of the treatment as determined by the incidence, nature, causality, frequency, timing and severity of adverse events using NCI CTCAE 5.0

    Time frame: AEs will be reported from start of trial treatment until 30 days after the last dose of study treatment or until initiation of another anti-cancer therapy, whichever occurs first, up to 13 months

Other outcomes

  1. Identifcation of molecular biomarkers

    to perform correlation analysis between selected molecular parameters and clinical data to identify molecular biomarkers predictive for clinical outcome

    Time frame: 27 months

07

Study locations

6 of 10 sites recruiting
  • Klinikum St. Marien Amberg
    Amberg, Germany
    Not yet recruiting
    • Ludwig Fischer von Weikersthal, Dr. · Contact
  • Charité Campus Virchow Klinikum (CVK)
    Berlin, Germany
    Not yet recruiting
    • Dominik P Modest, Prof. · Contact
  • Universitätsklinikum Düsseldorf
    Düsseldorf, Germany
    Recruiting
    • Christoph Roderburg, Prof. · Contact
  • Kliniken Essen-Mitte
    Essen, Germany
    Recruiting
    • Christian Müller, Dr. · Contact
  • Krankenhaus Nordwest
    Frankfurt am Main, 60488, Germany
    Recruiting
    • Thorsten O. Götze, Prof. Dr. · Contact
  • Hope Hamburg
    Hamburg, Germany
    Recruiting
    • Alexander Stein, Prof. · Contact
  • Universitätsmedizin Mainz
    Mainz, Germany
    Not yet recruiting
    • Markus Möhler, Prof. · Contact
  • Klinikum München rechts der Isar
    München, Germany
    Recruiting
    • Sylvie Lorenzen, Prof. · Contact
  • MVZ für Hämatologie und Onkologie Ravensburg GmbH
    Ravensburg, 88212, Germany
    Not yet recruiting
    • Tobias Dechow, Prof. · Contact
  • Leopoldina Krankenhaus Schweinfurt
    Schweinfurt, Germany
    Recruiting
    • Stephan Kanzler, Prof. · Contact
08

References and documents

Individual participant data

Plan to share: No — No IPD will be shared

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Mar 2028, 27 months later.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 27 months is below that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2024
First posted
Dec 9, 2024
StartEst.
Dec 16, 2025
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06722183
Lead sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators
Universitätsmedizin Mainz, I. Medizinische Klinik, Forschungslabor Prof. Möhler
Responsible party
Sponsor
First posted
Dec 9, 2024
Start date
Dec 16, 2025 (estimated)
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Dec 24, 2025

Study contacts

Thorsten O. Götze, Prof. Dr.
Contact
future@ikf-khnw.de
0049 69 7601 ext. 3788
Annika S. Stürzebecher, Dr.
Contact
future@ikf-khnw.de
0049 69 5899 787 ext. 10
Salah Al-Batran, Prof. Dr.
study director · Institut für Klinische Krebsforschung IKF GmbH
Thorsten O. Götze, Prof. Dr.
principal investigator · Institute of Clinical Cancer Research, UCT - University Cancer Center Frankfurt Krankenhaus Nordwest
Markus Möhler, Prof. Dr.
principal investigator · Johannes Gutenberg-University Clinic Mainz

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion